Leveraging Circulating Microbiome Signatures to Predict Tumor Immune Microenvironment and Prognosis of Patients with Non-small Cell Lung Cancer

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2023 Nov 11

PMID 37950236

Authors

Xiaohan Zhou

Liting You

Zhaodan Xin

Huiting Su

Juan Zhou

Ying Ma

Affiliations

Soon will be listed here.

Abstract

Background: Accumulating evidence supports the significant role of human microbiome in development and therapeutic response of tumors. Circulating microbial DNA is non-invasive and could show a general view of the microbiome of host, making it a promising biomarker for cancers. However, whether circulating microbiome is associated with prognosis of non-small cell lung cancer (NSCLC) and its potential mechanisms on tumor immune microenvironment still remains unknown.

Methods: The blood microbiome data and matching tumor RNA-seq data of TCGA NSCLC patients were obtained from Poore's study and UCSC Xena. Univariate and multivariate Cox regression analysis were used to identify circulating microbiome signatures associated with overall survival (OS) and construct the circulating microbial abundance prognostic scoring (MAPS) model. Nomograms integrating clinical characteristics and circulating MAPS scores were established to predict OS rate of NSCLC patients. Joint analysis of blood microbiome data and matching tumor RNA-seq data was used to deciphered the tumor microenvironment landscape of patients in circulating MAPS-high and MAPS-low groups. Finally, the predictive value of circulating MAPS on the efficacy of immunotherapy and chemotherapy were assessed.

Results: A circulating MAPS prediction model consisting of 14 circulating microbes was constructed and had an independent prognostic value for NSCLC. The integration of circulating MAPS into nomograms may improve the prognosis predictive power. Joint analysis revealed potential interactions between prognostic circulating microbiome and tumor immune microenvironment. Especially, intratumor plasma cells and humoral immune response were enriched in circulating MAPS-low group, while intratumor CD4 + Th2 cells and proliferative related pathways were enriched in MAPS-high group. Finally, drug sensitivity analysis indicated the potential of circulating MAPS as a predictor of chemotherapy efficacy.

Conclusion: A circulating MAPS prediction model was constructed successfully and showed great prognostic value for NSCLC. Our study provides new insights of interactions between microbes, tumors and immunity, and may further contribute to precision medicine for NSCLC.

Citing Articles

Microbial Biomarkers in Liquid Biopsy for Cancer: An Overview and Future Directions.

Luo F, Wang X, Ye C, Sun H Cancer Control. 2024; 31:10732748241292019.

PMID: 39431347 PMC: 11500238. DOI: 10.1177/10732748241292019.

Microbiota during pregnancy and early life: role in maternal-neonatal outcomes based on human evidence.

Fasano A, Chassaing B, Haller D, Flores Ventura E, Carmen-Collado M, Pastor N Gut Microbes. 2024; 16(1):2392009.

PMID: 39161102 PMC: 11340748. DOI: 10.1080/19490976.2024.2392009.

Early diagnosis of cancer using circulating microbial DNA.

Law H, Yim H Cell Rep Med. 2024; 5(4):101502.

PMID: 38631290 PMC: 11031418. DOI: 10.1016/j.xcrm.2024.101502.

References

Zhang S, Zhang S, Ma X, Zhan J, Pan C, Zhang H . Intratumoral microbiome impacts immune infiltrates in tumor microenvironment and predicts prognosis in esophageal squamous cell carcinoma patients. Front Cell Infect Microbiol. 2023; 13:1165790. PMC: 10174428. DOI: 10.3389/fcimb.2023.1165790. View

Colard-Thomas J, Thomas Q, Viala M . Comedications with Immune Checkpoint Inhibitors: Involvement of the Microbiota, Impact on Efficacy and Practical Implications. Cancers (Basel). 2023; 15(8). PMC: 10136801. DOI: 10.3390/cancers15082276. View

Zhang X, Wang J, Shao G, Wang Q, Qu X, Wang B . Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. Nat Commun. 2019; 10(1):1772. PMC: 6467893. DOI: 10.1038/s41467-019-09762-1. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Belkaid Y, Hand T . Role of the microbiota in immunity and inflammation. Cell. 2014; 157(1):121-41. PMC: 4056765. DOI: 10.1016/j.cell.2014.03.011. View

Peng R, Liu S, You W, Huang Y, Hu C, Gao Y . Gastric Microbiome Alterations Are Associated with Decreased CD8+ Tissue-Resident Memory T Cells in the Tumor Microenvironment of Gastric Cancer. Cancer Immunol Res. 2022; 10(10):1224-1240. DOI: 10.1158/2326-6066.CIR-22-0107. View

Zhang W, Zhao S, Luo J, Dong X, Hao Y, Li H . Alterations of fecal bacterial communities in patients with lung cancer. Am J Transl Res. 2018; 10(10):3171-3185. PMC: 6220220. View

Yu T, Guo F, Yu Y, Sun T, Ma D, Han J . Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell. 2017; 170(3):548-563.e16. PMC: 5767127. DOI: 10.1016/j.cell.2017.07.008. View

Lohr M, Edlund K, Botling J, Hammad S, Hellwig B, Othman A . The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett. 2013; 333(2):222-8. DOI: 10.1016/j.canlet.2013.01.036. View

10.

Zhou Y, Zhang Y, Guo G, Cai X, Yu H, Cai Y . Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer. Clin Transl Med. 2020; 10(1):107-115. PMC: 7240850. DOI: 10.1002/ctm2.14. View

11.

Jain T, Sharma P, Are A, Vickers S, Dudeja V . New Insights Into the Cancer-Microbiome-Immune Axis: Decrypting a Decade of Discoveries. Front Immunol. 2021; 12:622064. PMC: 7940198. DOI: 10.3389/fimmu.2021.622064. View

12.

Chung L, Thiele Orberg E, Geis A, Chan J, Fu K, DeStefano Shields C . Bacteroides fragilis Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells. Cell Host Microbe. 2018; 23(2):203-214.e5. PMC: 5954996. DOI: 10.1016/j.chom.2018.01.007. View

13.

Luu M, Schutz B, Lauth M, Visekruna A . The Impact of Gut Microbiota-Derived Metabolites on the Tumor Immune Microenvironment. Cancers (Basel). 2023; 15(5). PMC: 10001145. DOI: 10.3390/cancers15051588. View

14.

Pushalkar S, Hundeyin M, Daley D, Zambirinis C, Kurz E, Mishra A . The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discov. 2018; 8(4):403-416. PMC: 6225783. DOI: 10.1158/2159-8290.CD-17-1134. View

15.

Cho E, Leem S, Kim S, Yang J, Lee Y, Kim S . Circulating Microbiota-Based Metagenomic Signature for Detection of Hepatocellular Carcinoma. Sci Rep. 2019; 9(1):7536. PMC: 6525191. DOI: 10.1038/s41598-019-44012-w. View

16.

Oh B, Boyle F, Pavlakis N, Clarke S, Eade T, Hruby G . The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?. Cancers (Basel). 2021; 13(19). PMC: 8508052. DOI: 10.3390/cancers13194824. View

17.

Sharonov G, Serebrovskaya E, Yuzhakova D, Britanova O, Chudakov D . B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat Rev Immunol. 2020; 20(5):294-307. DOI: 10.1038/s41577-019-0257-x. View

18.

Gharaibeh R, Jobin C . Microbiota and cancer immunotherapy: in search of microbial signals. Gut. 2018; 68(3):385-388. PMC: 6580757. DOI: 10.1136/gutjnl-2018-317220. View

19.

Boesch M, Baty F, Rothschild S, Tamm M, Joerger M, Fruh M . Tumour neoantigen mimicry by microbial species in cancer immunotherapy. Br J Cancer. 2021; 125(3):313-323. PMC: 8329167. DOI: 10.1038/s41416-021-01365-2. View

20.

Liu C, Yu H, Li X, Gong Y, Wu P, Feng Q . Anti-hepatocellular carcinoma efficacy of Fuzheng Xiaozheng prescription and its interventional mechanism studies. J Ethnopharmacol. 2021; 285:114913. DOI: 10.1016/j.jep.2021.114913. View